Efficacy, tolerability, compliance, and quality of life of patients with mood disorders switched from quetiapine immediate release to extended release

B Dell'Osso, C Arici, C Dobrea, B Benatti… - International clinical …, 2012 - journals.lww.com
The present study aimed to assess switch from immediate-release (IR) to extended-release
(XR) Quetiapine in terms of efficacy, tolerability, compliance, and quality of life in a sample of
patients with mood disorders. Thirty patients, 10 with major depressive disorder and 20 with
bipolar disorder, with residual depressive symptoms, who had switched from Quetiapine IR
(mean 365 mg/day) to XR (mean 373 mg/day), were recruited and evaluated using different
psychometric scales, administered at T0 (switch), T1, and T2 (1 and 6 weeks after the switch …
以上显示的是最相近的搜索结果。 查看全部搜索结果